Last reviewed · How we verify
Nefopam administration and prelevment
Nefopam is a non-opioid analgesic that inhibits the reuptake of monoamines (norepinephrine, dopamine, and serotonin) in the central nervous system to produce analgesia.
Nefopam is a non-opioid analgesic that inhibits the reuptake of monoamines (norepinephrine, dopamine, and serotonin) in the central nervous system to produce analgesia. Used for Postoperative pain, Acute pain management.
At a glance
| Generic name | Nefopam administration and prelevment |
|---|---|
| Sponsor | University Hospital, Rouen |
| Drug class | Non-opioid analgesic; monoamine reuptake inhibitor |
| Target | Norepinephrine transporter, dopamine transporter, serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Nefopam works by blocking the reuptake of catecholamines and serotonin at nerve terminals, increasing their synaptic concentration and enhancing pain modulation pathways. Unlike opioids, it does not bind to opioid receptors and has a different mechanism of action, making it useful as an alternative or adjunctive analgesic. It is commonly used perioperatively and for moderate pain management.
Approved indications
- Moderate acute pain (perioperative and postoperative pain management)
- Moderate chronic pain
Common side effects
- Nausea
- Sweating
- Tachycardia
- Tremor
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: